PegBio Co., Ltd.
派格生物醫藥(杭州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2565)

VOLUNTARY ANNOUNCEMENT
PEGBIO RECEIVES FIRST ROYALTY PAYMENT OF HK$61 MILLION FROM TENRY PHARMACEUTICAL FOR VISEPEGENATIDE COMMERCIALIZATION COLLABORATION

This announcement is made by PegBio Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors informed of the latest progress of the Group's commercialization collaboration.

Reference is made to the announcement of the Company dated March 16, 2026 in relation to the collaboration arrangement between the Group and Shanghai Tenry Pharmaceutical Co., Ltd. (上海騰瑞製藥股份有限公司) ("**Tenry Pharmaceutical**") for the commercial promotion of Visepegenatide injection (Paidakang®) (派達康®), a Class 1 new drug independently developed by the Group in the Chinese mainland.

The board (the "**Board**") of directors of the Company is pleased to announce that, pursuant to the commercialization collaboration agreement executed by both parties, the Group has received the first royalty payment of HK$61 million from Tenry Pharmaceutical. The successful receipt of such payment marks the commercialization collaboration concerning Paidakang® (派達康®) between both parties in the Chinese mainland has entered into the stage of substantial performance and comprehensive advancement, further demonstrating the counterparty's recognition of the clinical value, market potential and long-term commercialization prospects of Paidakang® (派達康®).

Paidakang® (派達康®) is a long-acting GLP-1 receptor agonist independently developed by the Group and approved for marketing by the National Medical Products Administration for the treatment of type 2 diabetes. The product features once-weekly administration, initiation of treatment without dose titration, and has demonstrated stable glycemic control, weight management benefits and a favorable safety profile in pivotal clinical studies.

The Group will continue to work in close collaboration with Tenry Pharmaceutical to steadily advance the commercialization of Paidakang® (派達康®) in the Chinese mainland, including market access, pipeline development, academic promotion and terminal coverage, so as to accelerate the realization of the product's clinical and commercial value and help enhance the long-term treatment management level of patients with type 2 diabetes in China.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PegBio Co., Ltd.
Michael Min XU
Chairman of the Board, Executive Director and General Manager

Hong Kong, June 5, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG and Dr. Yangyang CHEN as independent non-executive directors.